MADISON MOSAIC SERIES

4Q 2020 Investment Strategy Letter - SMA



2020 YEAR-END RECAP

Supported by unprecedented levels of fiscal stimulus, ongoing global central bank accommodation, quickly recovering corporate profits, and encouraging news on the Covid-19 vaccine front, risk assets continued their steady and impressive ascent since first putting in their pandemic-related panic lows this past March. For the year, U.S. equities (Russell 3000) rose 20.9% while foreign equities (MSCI ACWI-ex U.S.) climbed 10.7%. U.S. bonds (Barclays U.S. Aggregate) returned 7.5% as interest rates, once again, declined for much of the year.

PERSPECTIVES

"Ignorance more frequently begets confidence than does knowledge ..."

- Charles Darwin

Financial markets are partying like its 1999. Literally. The best explanation for today's full-blown giddiness is that this is exactly what nearly all global central banks seemingly desire. They want elevated asset prices and they are taking historically extreme actions to accomplish this. Surging financial markets clearly provide an important psychological boost to otherwise ailing and fragile economies. Importantly, a key prerequisite for this storyline to play out like it has, so far, is that inflation is also cooperating and remains accommodatingly low. Conversely, high and/or rapidly rising inflation would stifle the effectiveness (and wisdom) of posturing to a radically dovish monetary policy. Thankfully, that is not yet the case.

The current and obvious motive for central banks to take the drastic measures they have taken is that pandemic-scarred and debt-infected global economies remain acutely in need of big-time financial assistance. With no perceived threat of inflation, central banks are not only willing, they also believe they are wholly and justifiably able to respond in-kind to the ongoing pandemic-related crisis. Accordingly, central banks have slashed interest rates while massively increasing both quantitative easing (QE) and overall liquidity. Perhaps more importantly to U.S. investors, the Federal Reserve (Fed) remains (since March 2020) authorized (as needed) to purchase non-government issued debt securities, such as U.S. corporate bonds. This assertive (intrusive) level of direct involvement in U.S. financial markets has clearly emboldened investors over the final nine months of 2020. To date, the Fed is pleased that its uncharted stimulus plan is working largely as hoped.

With the notable exception of China, many large global economies are following similar playbooks. China, is taking a more moderate and cautious tactic, choosing rather to cultivate a longer-term focus while maintaining more "normalized" financial markets. As we move through and beyond this current crisis, China's approach will likely serve them well. Meanwhile, the Fed and U.S. investors appear equally confident that they will know when to say when. But will they? This current "easy button" narrative is seemingly unquestioned by many. Record high investor complacency metrics lend support to this observation. Our question remains – who is acting responsibly and who is acting "confidently"? We'll let the answer to that be our guide.

OUTLOOK & POSITIONING

By nearly any measure, we now "live" in a world of both uncomfortable extremes and disorienting disruptions. Our collective experiences in 2020 undoubtedly testify to that. We believe this recent "recipe" for elevated uncertainty is likely to persist. Accordingly, we also expect to see ongoing bouts of elevated volatility. We know there are always winners and losers, but in a world of extremes, the differences between the "haves" and the "have-nots" is likely to



MADISON MOSAIC SERIES

4Q 2020 Investment Strategy Letter - SMA



be exaggerated. In other words, we can anticipate scenarios where winners really win, and losers really lose. This increases the risks and the opportunities for all investors. By implication, not losing takes on greater importance. In short, management matters, arguably now more than ever.

Our conviction in a structurally weaker U.S. dollar (USD) is growing, especially relative to Asian currencies, as the U.S. continues to create and perpetuate unprecedented levels of fiscal and monetary stimulus. A weaker USD would likely benefit international equities and commodities, including gold. Our portfolios are strategically aligned to capitalize on this theme.

Throughout 2020, portfolios were tactically positioned to emphasize the increasingly attractive Asia-Pacific region, including countries such as Japan, China, Taiwan and South Korea. China was the first country to emerge from the COVID lockdowns; it was also able to do so while remaining uniquely conservative with its monetary and fiscal policies. Unlike many other countries, the Chinese Communist Party (CCP) has vowed to minimize the risk of creating destabilizing economic boom and bust cycles. Still, as economic growth remains important to the CCP, especially moving into the year of the party's 100-year anniversary, we don't foresee this moderating posture as a hindrance to the health of the Chinese equity markets. To the contrary, we believe that the broader Asia-Pacific region will continue to provide long-term global investors with an array of attractive opportunities going forward.

Finally, news on the Covid-19 vaccine front has been nothing short of remarkable. Going back to March, we learned that it would take at least 12 to 18 months to develop an effective vaccine. Now, just nine months later, we have two vaccines, from Pfizer and Moderna, that the U.S. is already administering. These vaccines, with indications of greater than 90% efficacy, are based on breakthrough mRNA coding. This technology is uniquely well-designed to stimulate a wide-ranging and effective antibody reaction, improving both the safety and likely durability of the immune response. Medical advancements like this also demonstrate the degree of overall technological progress that has been accomplished in recent years. Sectors with strong emphases on research and development have proven to be historically attractive and remain an area of focus in our portfolios. Biotechnology and (information) technology are two prime examples.

SUMMARY

We are confident our portfolios remain well-positioned for a still stressed global economy. We also embrace our ongoing responsibility to insightfully differentiate between attractive and less attractive asset classes as we strive to deliver superior risk-adjusted returns. As we continue to work through these difficult times as a nation, we truly appreciate your confidence in partnering with us.

Disclosures

Indices are unmanaged. An investor cannot invest directly in an index. They are shown for illustrative purposes only, and do not represent the performance of any specific investment. Index returns do not include any expenses, fees or sales charges, which would lower performance.

Russell Investment Group is the source and owner of the trademarks, service marks and copyrights related to the Russell Indexes. Russell® is a trademark of Russell Investment Group.

The Russell 3000 Index measures the performance of the largest 3,000 U.S. companies representing approximately 98% of the investable U.S. equity market. The Russell 3000 Index is constructed to provide a comprehensive, unbiased and stable barometer of the broad market and is completely reconstituted annually to ensure new and growing equities are reflected.

The MSCI ACWI ex USA Index captures large and mid cap representation across 22 of 23 Developed Markets countries (excluding the US) and 23 Emerging Markets countries. With 1,843 constituents, the index covers approximately 85% of the global equity opportunity set outside the US.

Bloomberg Barclays U.S. Aggregate Bond Index is an unmanaged index of U.S. fixed income securities. The U.S. Aggregate Index covers the USD-denominated, investment-grade, fixed-rate, taxable bond market of SEC-registered securities. The index includes bonds from the Treasury, Government-Related, Corporate, MBS (agency fixed-rate and hybrid ARM passthroughs), ABS, and CMBS sectors.

"Madison" and/or "Madison Investments" is the unifying tradename of Madison Investment Holdings, Inc., Madison Asset Management, LLC ("MAM"), and Madison Investment Advisors, LLC ("MIA"), which also includes the Madison Scottsdale office. MAM and MIA are registered as investment advisers with the U.S. Securities and Exchange Commission. Madison Funds are distributed by MFD Distributor, LLC. MFD Distributor, LLC is registered with the U.S. Securities and Exchange Commission as a broker-dealer and is a member firm of the Financial Industry Regulatory Authority. The home office for each firm listed above is 550 Science Drive, Madison, WI 53711. Madison's toll-free number is 800-767-0300.

Any performance data shown represents past performance. Past performance is no guarantee of future results.

Non-deposit investment products are not federally insured, involve investment risk, may lose value and are not obligations of, or guaranteed by, any financial institution. Investment returns and principal value will fluctuate.

This report is for informational purposes only and is not intended as an offer or solicitation with respect to the purchase or sale of any security.

Principal values of the funds are not guaranteed at any time, including at the time of target date and/or withdrawal. The funds are not a complete retirement program and there is no guarantee that the funds will provide sufficient retirement income to an investor. The funds seek to achieve the stated objectives but there is no guarantee the objectives will be met.

Although the information in this report has been obtained from sources that the firm believes to be reliable, we do not guarantee its accuracy, and any such information may be incomplete or condensed. All opinions included in the report constitute the authors' judgment as of the date of this report and are subject to change without notice. This report is for informational purposes only and is not intended as an offer or solicitation with respect to the purchase or sale of any security.

Madison Asset Management, LLC does not provide investment advice directly to shareholders of the Madison Funds. Opinions stated are informational only and should not be taken as investment recommendation or advice of any kind whatsoever (whether impartial or otherwise).